SCHEMBL23383883

SCHEMBL23383883

C=C(CCNC(=O)COc1ccc(Cl)cc1)NC(=O)CNCC

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.49
▸ MEN1 O00255 6/20 0.47
▸ KMT2A Q03164 6/20 0.47
▸ HTT P42858 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ HDAC1 Q13547 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ BCHE P06276 1/20 0.45
▸ ACHE P22303 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ NPY1R P25929 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23383882 0.92 KDM4E (0.48) KDM4EMEN1KMT2AHTTSMN1; SMN2
SCHEMBL23383660 0.88 KDM4E (0.51) KDM4EMEN1KMT2AHTTSMN1; SMN2
SCHEMBL23383779 0.88 MEN1 (0.50) KDM4EMEN1KMT2AHTTSMN1; SMN2
SCHEMBL23383748 0.88 CYP1A2 (0.49) KDM4EMEN1KMT2AHTTSMN1; SMN2
SCHEMBL23182908 0.88 KDM4E (0.54) KDM4EMEN1KMT2AHTTSMN1; SMN2
SCHEMBL23384172 0.87 MEN1 (0.49) KDM4EMEN1KMT2AHTTSMN1; SMN2
SCHEMBL23383996 0.85 MEN1 (0.50) KDM4EMEN1KMT2AHTTSMN1; SMN2
SCHEMBL23182881 0.85 HDAC1 (0.61) KDM4EMEN1KMT2AHTTSMN1; SMN2
SCHEMBL23384162 0.85 KMT2A (0.49) KDM4EMEN1KMT2AHTTSMN1; SMN2
SCHEMBL23383744 0.84 HTT (0.57) KDM4EMEN1KMT2AHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210145771-A1 N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210145771-A1 N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES ATF4, EIF2B1, EIF4A1 KDM4E 2283/4885MEN1 4354/4885KMT2A 2778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback